| --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | NeueHealth Second Quarter 2024 - Earnings Presentation | | | | | | Privileged & Confidential \| © 2024 August 7, 2024 | | | | | Disclaimer Statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward- ...

Financial Data and Key Metrics Changes - NeueHealth reported consolidated revenue of $226 million for Q2 2024, with a gross margin of $48.3 million and adjusted EBITDA of $4 million, indicating a moderate increase in consumers served compared to Q1 [13][19] - The company reaffirmed its expectation for full-year adjusted EBITDA to be between $15 million and $25 million [19] Business Line Data and Key Metrics Changes - In the NeueCare segment, revenue was $77 million, with operating income of $8.5 million before a long-lived asset impairment expense, which resulted in an operating loss of $5.9 million for the quarter [14] - The NeueSolutions segment generated revenue of $152.1 million, with an operating loss of $397,000, while serving approximately 113,000 consumers, exceeding expectations [15][11] Market Data and Key Metrics Changes - The company served over 477,000 consumers across the ACA Marketplace, Medicare, and Medicaid in Q2 2024, reflecting its ability to manage diverse populations [6][13] - For 2024, NeueHealth expects to serve between 475,000 and 500,000 consumers across both segments, with specific targets for value-based consumers [19] Company Strategy and Development Direction - NeueHealth is focused on a value-driven, consumer-centric care model that emphasizes long-term relationships with consumers and partnerships with providers [5][6] - The company is evaluating strategic growth opportunities and has a robust pipeline for 2025 and beyond, aiming to expand payer and provider partnerships [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's model and its ability to drive better health outcomes, highlighting the importance of consumer engagement and personalized care [5][21] - The company is well-positioned for sustainable growth in 2024 and beyond, supported by a new term loan facility of up to $150 million [4][18] Other Important Information - The wind-down of the ACA insurance business is progressing as planned, with approximately $135 million in excess cash at the end of Q2 2024 [16] - As of June 30, 2024, the company had $277.8 million in total cash and investments, strengthening its balance sheet [17] Summary of Q&A Session - The Q&A session concluded without any recorded questions or answers, indicating a focus on the presentation of results rather than interactive discussion [22]

Exhibit 99.1 NEUEHEALTH REPORTS SECOND QUARTER 2024 RESULTS | --- | --- | --- | |------------------------------------|-----------------------|------------| | Key Metrics | As of June \n2024 | 30, \n2023 | | Consumer and Patient Metrics | | | | Value-Based Consumers served | 364,000 | 373,000 | | Enablement Services Lives | 113,000 | 31,000 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------|-------|---------------------|----------------|------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40537 NEUEHEALTH, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4991296 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or oth ...

NeueHealth, Inc. (NYSE:NEUE) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Emily Lombardi - Investor Relations Mike Mikan - President and Chief Executive Officer Jay Matushak - Chief Financial Officer Conference Call Participants Marco Criscuolo - Nephron Research LLC Operator Good morning, everyone, and welcome to the NeueHealth Q1 2024 Earnings Call. My name is Drew, and I'll be the operator for today. After today's presentation, we will begin the Q&A session. [Operator Inst ...

Exhibit 99.1 NEUEHEALTH REPORTS FIRST QUARTER 2024 RESULTS DORAL, Fla. (May 8, 2024) (BUSINESSWIRE) – NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE: NEUE), the value- driven healthcare company, today reported financial results for its First Quarter ended March 31, 2024. "We had a strong start to the year, continuing to advance our value-driven, consumer-centric care model as we build on our strong relationships with providers and payors to make high-quality healthcare more accessible and affordable ...

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Registrant's telephone number, including area code: (612) 238-1321 For the transition period from to Commission file number 001-40537 NEUEHEALTH, INC. (Exact Name of Registrant as ...

NeueHealth, Inc. Q4 2023 Earnings Conference Call March 6, 2024 12:00 AM ET Company Participants Emily Lombardi - Investor Relations Mike Mikan - President and CEO Jay Matushak - CFO Tomas Orozco - Executive Vice President Conference Call Participants Joshua Raskin - Nephron Research Operator Good morning. My name is Drew, and I'll be your conference operator today. At this time, I would like to welcome everyone to the NeueHealth Q4 2023 Earnings Conference Call. All lines have been placed on mute to preven ...

Exhibit 99.1 For full year 2024, NeueHealth is providing the following guidance and commentary: NEUEHEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2023 RESULTS DORAL, Fla. (March 6, 2024) (BUSINESSWIRE) – NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE: NEUE), the value-driven healthcare company, today reported financial results for its fourth quarter and full year ended December 31, 2023. "We achieved significant milestones as a company this past year, completing the sale of our California Medicare Adv ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR Commission File Number: 001-40537 BRIGHT HEALTH GROUP, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 47-4991 ...